The patent application WO2008106213 describes the beneficial effects of thyroid 
hormone analogue 3,5 diiodothyropropionic acid (DITPA) such as stimulating 
weight loss in overweight mammals, lowering of triglyceride and treating 
metabolic syndrome in humans. The human population of the patients selected in 
the studies mentioned has a body mass index > 25. Two examples of the human 
clinical studies employing DITPA have been mentioned, namely, the body weight 
reduction and improvement in metabolic abnormalities in obese adults.